These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 2092110)

  • 21. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
    Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
    Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The level of soluble interleukin 2 receptor in esophageal carcinoma patients before and after radiotherapy].
    Liu X; An H; Jiang Y
    Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):97-9. PubMed ID: 7656815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-surface-bound circulating DNA as a prognostic factor in lung cancer.
    Tamkovich SN; Litviakov NV; Bryzgunova OE; Dobrodeev AY; Rykova EY; Tuzikov SA; Zav'ialov AA; Vlassov VV; Cherdyntseva NV; Laktionov PP
    Ann N Y Acad Sci; 2008 Aug; 1137():214-7. PubMed ID: 18837949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble interleukin-2 receptor: a new marker in pancreatic adenocarcinoma?
    Rabitti PG; Pacelli L; Uomo G; Laccetti M; Spada OA; Esposito G; Visconti M
    Minerva Gastroenterol Dietol; 1994 Sep; 40(3):101-3. PubMed ID: 7948318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
    Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
    Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tumor markers in malignant lymphoma].
    Kato H; Ogura M
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):883-92. PubMed ID: 15984537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Serum soluble interleukin-2 receptor in patients with pulmonary mycobacterial diseases].
    Tada A; Kawahara S; Horita N; Horiba A; Tamaoki A; Okada C; Mishima Y; Soda R; Takahashi K
    Kekkaku; 1999 Jun; 74(6):499-505. PubMed ID: 10423961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Soluble interleukin-2 receptor in patients with urinary bladder cancer].
    Wen R; Xie S
    Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):224-6. PubMed ID: 9387261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The detection of quantitative serum p53 protein in lung cancer.
    Sen E; Gönüllü U; Akar N
    Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of soluble interleukin-2 receptor and serum lactate dehydrogenase in malignant lymphoma.
    Tomita N; Taguri M; Hashimoto C; Takasaki H; Fujimaki K; Motomura S; Koharazawa H; Takemura S; Fujita H; Yamazaki E; Kawasaki R; Taguchi J; Sakai R; Fujisawa S; Hattori Y; Kanamori H; Yamamoto W; Harano H; Ogawa K; Ishigatsubo Y
    Ann Hematol; 2015 Nov; 94(11):1935-7. PubMed ID: 26208667
    [No Abstract]   [Full Text] [Related]  

  • 32. Internal organ lesions in acrosclerosis patients: interleukin-2 and soluble receptor for interleukin-2 plasma levels.
    Chibowska M; Krasowska D; Weglarz J
    J Eur Acad Dermatol Venereol; 2000 May; 14(3):234-6. PubMed ID: 11032081
    [No Abstract]   [Full Text] [Related]  

  • 33. Follow-up study of soluble interleukin-2 receptor serum levels in non-progressing HIV-infected people.
    Lang JM; Levy S; Coumaros G; Lehr L; Partisani M; Dossou-Gbete V; Steckmeyer M; Koehl C
    AIDS; 1989 Oct; 3(10):673-4. PubMed ID: 2512960
    [No Abstract]   [Full Text] [Related]  

  • 34. Reference values of soluble interleukin-2 receptor on the IMMULITE.
    Rothkrantz-Kos S; Drent M; Schmitz MP; Menheere PP; van Dieijen-Visser MP
    Clin Chem Lab Med; 2004; 42(8):976-7. PubMed ID: 15387453
    [No Abstract]   [Full Text] [Related]  

  • 35. Soluble interleukin-2 receptors and psoriasis.
    Dummer R; Dunkel FG
    Arch Dermatol Res; 1991; 283(2):138-9. PubMed ID: 2069414
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of mucin like cancer associated antigen (MCA) in the management of breast cancer.
    Laurence V; Forbes MA; Cooper EH
    Br J Cancer; 1991 Jun; 63(6):1000-4. PubMed ID: 2069833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble interleukin-2 receptor: a new prognostic marker in lung cancer.
    Marino P; Buccheri G; Preatoni A; Ferrigno D; Cori P; Rosti A; Mozzi R; Moroni GA
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):151-4. PubMed ID: 2092110
    [No Abstract]   [Full Text] [Related]  

  • 38. Interleukin 2 soluble receptor (s-IL 2R) and lung cancer.
    Pecchio F; Rapellino M; Aimo G; Baldi S; Cunazza M; Libertucci D; Cavallo A; Oliaro A; Pagni R
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):163-7. PubMed ID: 2092112
    [No Abstract]   [Full Text] [Related]  

  • 39. [The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients].
    Siemińska A
    Pol Merkur Lekarski; 2004 Feb; 16(92):188-90. PubMed ID: 15176308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.